Access to anti-retroviral drugs, male in Armenia

Armenia: Access to anti-retroviral drugs, male was 52.0% in 2024. ◆ Volatile

Latest (2024)
52.0%
Change on year
up 8.3%
World rank
113th
of 141 countries
All-time high
52.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Armenia, 2000–2024

02040602000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 6 %2006: 7 %2007: 9 %2008: 9 %2009: 13 %2010: 16 %2011: 17 %2012: 18 %2013: 20 %2014: 23 %2015: 26 %2016: 29 %2017: 34 %2018: 38 %2019: 42 %2020: 40 %2021: 43 %2022: 48 %2023: 48 %2024: 52 %

Source: UNAIDS estimates. Measured in %.

Analysis

Armenia recorded 52.0% for access to anti-retroviral drugs, male in 2024. That is the highest value across all 25 years on record.

The figure is up 8.3% on the previous year and up 126.1% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Armenia peaked at 52.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Armenia 113th out of 141 countries with data for 2024, putting it in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Armenia, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Armenia, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 6.0%
2006 7.0% +16.7%
2007 9.0% +28.6%
2008 9.0% +0.0%
2009 13.0% +44.4%
2010 16.0% +23.1%
2011 17.0% +6.2%
2012 18.0% +5.9%
2013 20.0% +11.1%
2014 23.0% +15.0%
2015 26.0% +13.0%
2016 29.0% +11.5%
2017 34.0% +17.2%
2018 38.0% +11.8%
2019 42.0% +10.5%
2020 40.0% -4.8%
2021 43.0% +7.5%
2022 48.0% +11.6%
2023 48.0% +0.0%
2024 52.0% +8.3%

Averages by decade

DecadeAverage LowestHighest Years
2000s 4.4% 0.0% 13.0% 10
2010s 26.3% 16.0% 42.0% 10
2020s 46.2% 40.0% 52.0% 5

Countries ranked near Armenia

  1. 110 Niger 56.0% compare
  2. 110 Senegal 56.0% compare
  3. 112 Bahrain 53.0% compare
  4. 113 Angola 52.0% compare
  5. 113 South Sudan 52.0% compare
  6. 116 Latvia 51.0% compare

See the full ranking of 160 places →

More gender data for Armenia

All data for Armenia →

Frequently asked questions

What is access to anti-retroviral drugs, male in Armenia?
Access to anti-retroviral drugs, male in Armenia was 52.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Armenia?
The highest recorded value was 52.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Armenia?
The lowest recorded value was 0.0% in 2000.
How does Armenia rank for access to anti-retroviral drugs, male?
Armenia ranks 113th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Armenia?
Over the last ten years it is up 126.1%. The long-run trend across the full record is volatile.
Where does this Armenia data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Armenia. Statizoid, drawing on UNAIDS estimates. Retrieved 12 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/armenia/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/armenia/">Access to anti-retroviral drugs, male in Armenia</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.